HSD3B1 and prostate cancer: For example, HSD3B1-specific pro-drugs could prove useful to treat castration-resistant prostate cancers, since the stabilized N367T variant of this SDR, found in ~30% of the population (rs1047303), has been associated to resistance to androgen deprivation therapies by allowing self-sufficient production of pro-proliferative androgens by prostate cancer cells (Chang et al., 2013; Hearn et al., 2020; Thomas and Sharifi, 2020).